|
| TROP2 | TM9SF2 | TSPAN6 | NGFR | ||||||||
| Low | High | p | Low | High | p | Low | High | p | Low | High | p | |
| Gender | ||||||||||||
| Male | 10 (62.5) | 5 (35.7) | 0.27 | 7 (50.0) | 9 (56.3) | 1.00 | 7 (58.3) | 12 (66.7) | 0.71 | 7 (53.8) | 9 (52.9) | 1.00 |
| Female | 6 (37.5) | 9 (64.3) | 7 (50.0) | 7 (43.8) | 5 (41.7) | 6 (33.3) | 6 (46.2) | 8 (47.1) | ||||
| Age |
|
|
|
|
|
|
|
|
|
|
|
|
| <65 | 5 (31.3) | 4 (28.6) | 1.00 | 6 (42.9) | 7 (43.8) | 1.00 | 6 (50.0) | 10 (55.6) | 1.00 | 7 (53.8) | 11 (64.7) | 0.54 |
| ≥65 | 11 (68.8) | 10 (71.4) | 8 (57.1) | 9 (56.3) | 6 (50.0) | 8 (44.4) | 6 (46.2) | 6 (35.3) | ||||
| Location | ||||||||||||
| Colon | 6 (37.5) | 4 (28.6) | 0.41 | 5 (35.7) | 6 (37.5) | 0.83 | 3 (25.0) | 5 (27.8) | 0.46 | 7 (53.8) | 9 (52.9) | 0.57 |
| Rectum | 6 (37.5) | 7 (50.0) | 7 (50.0) | 9 (56.3) | 9 (75.0) | 9 (50.0) | 5 (38.5) | 5 (29.4) | ||||
| Other | 4 (25.0) | 3 (21.4) | 2 (14.3) | 1 (6.2) | 0 (0) | 4 (22.2) | 1 (7.7) | 3 (17.7) | ||||
| Histological grade | ||||||||||||
| WD | 2 (12.5) | 2 (14.3) | 0.37 | 5 (35.7) | 3 (18.8) | 0.12 | 4 (33.3) | 5 (27.8) | 0.53 | 4 (30.8) | 4 (23.5) | 0.60 |
| MD | 14 (87.5) | 9 (64.3) | 7 (50.0) | 13 (81.2) | 7 (58.3) | 13 (72.2) | 9 (69.2) | 11 (64.7) | ||||
| PD | 0 (0) | 1 (7.1) | 2 (14.3) | 0 (0) | 1 (8.4) | 0 (0) | 0 (0) | 2 (11.8) | ||||
| Stage | ||||||||||||
| Early | 6 (37.5) | 6 (42.9) | 1.00 | 8 (57.1) | 8 (50.0) | 0.73 | 3 (25.0) | 6 (33.3) | 0.70 | 9 (69.2) | 12 (70.6) | 1.00 |
| Late | 10 (62.5) | 8 (57.1) | 6 (42.9) | 8 (50.0) | 9 (75.0) | 12 (66.7) | 4 (30.8) | 5 (29.4) | ||||
| T stage | ||||||||||||
| T1-T2 | 6 (37.5) | 6 (42.9) | 1.00 | 3 (21.4) | 2 (13.3) | 0.56 | 2 (20.0) | 2 (14.3) | 1.00 | 1 (7.7) | 3 (18.8) | 0.60 |
| T3-T4 | 10 (62.5) | 8 (57.1) | 11 (78.6) | 13 (86.7) | 8 (80.0) | 12 (85.8) | 12 (92.3) | 13 (81.3) | ||||
| Lymph node metastasis | ||||||||||||
| Negative | 9 (56.2) | 8 (57.1) | 1.00 | 8 (57.1) | 8 (50.0) | 0.69 | 3 (25.0) | 9 (50.0) | 0.26 | 9 (69.2) | 12 (70.6) | 1.00 |
| Positive | 7 (43.8) | 6 (42.9) | 6 (42.9) | 8 (50.0) | 9 (75.0) | 9 (50.0) | 4 (30.8) | 5 (29.4) | ||||
| CEA | ||||||||||||
| <5 | 10 (62.5) | 6 (42.9) | 0.46 | 9 (64.3) | 6 (37.5) | 0.27 | 6 (50.0) | 11 (61.1) | 0.71 | 7 (53.8) | 7 (41.2) | 0.83 |
| ≥5 | 6 (37.5) | 8 (57.1) | 5 (35.7) | 9 (56.3) | 6 (50.0) | 7 (38.9) | 6 (46.2) | 9 (52.9) | ||||
| 5-year survival | ||||||||||||
| <5 | 6 (37.5) | 6 (42.9) | 1.00 | 6 (42.9) | 10 (62.5) | 0.46 | 6 (50.0) | 11 (61.1) | 0.71 | 4 (30.8) | 8 (47.1) | 0.36 |
| ≥5 | 10 (62.5) | 8 (57.1) | 8 (57.1) | 6 (37.5) | 6 (50.0) | 7 (38.9) | 9 (69.2) | 9 (52.9) | ||||